AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
Biologics by McKesson joined the limited distribution network for AUGTYRO, approved for ROS1-positive non-small cell lung cancer and certain NTRK gene fusion-positive solid tumors.
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for IBTROZI, a next-generation ROS1 inhibitor for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.